These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21382717)

  • 21. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents.
    Abdizadeh R; Heidarian E; Hadizadeh F; Abdizadeh T
    Anticancer Agents Med Chem; 2021; 21(8):987-1018. PubMed ID: 32698753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.
    Hanessian S; Auzzas L; Giannini G; Marzi M; Cabri W; Barbarino M; Vesci L; Pisano C
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6261-5. PubMed ID: 17892933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and Structural Evaluation of N-Alkylated trans-2-Phenylcyclopropylamine-Based LSD1 Inhibitors.
    Niwa H; Sato S; Handa N; Sengoku T; Umehara T; Yokoyama S
    ChemMedChem; 2020 May; 15(9):787-793. PubMed ID: 32166890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and evaluation of 3-amino/guanidine substituted phenyl oxazoles as a novel class of LSD1 inhibitors with anti-proliferative properties.
    Dulla B; Kirla KT; Rathore V; Deora GS; Kavela S; Maddika S; Chatti K; Reiser O; Iqbal J; Pal M
    Org Biomol Chem; 2013 May; 11(19):3103-7. PubMed ID: 23575971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
    Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
    Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor.
    Wang X; Su M; Li Y; Liu T; Wang Y; Chen Y; Tang L; He YP; Ding X; Yu F; Shen J; Li J; Zhou Y; Chen YL; Xiong B
    Bioorg Med Chem Lett; 2019 Mar; 29(6):844-847. PubMed ID: 30713023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of cell-active lysine specific demethylase 1-selective inhibitors.
    Ueda R; Suzuki T; Mino K; Tsumoto H; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N
    J Am Chem Soc; 2009 Dec; 131(48):17536-7. PubMed ID: 19950987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor.
    Ogasawara D; Suzuki T; Mino K; Ueda R; Khan MN; Matsubara T; Koseki K; Hasegawa M; Sasaki R; Nakagawa H; Mizukami T; Miyata N
    Bioorg Med Chem; 2011 Jun; 19(12):3702-8. PubMed ID: 21227703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors.
    Qiu X; Liu Z; Shao WY; Liu X; Jing DP; Yu YJ; An LK; Huang SL; Bu XZ; Huang ZS; Gu LQ
    Bioorg Med Chem; 2008 Sep; 16(17):8035-41. PubMed ID: 18678491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 A.
    Mimasu S; Sengoku T; Fukuzawa S; Umehara T; Yokoyama S
    Biochem Biophys Res Commun; 2008 Feb; 366(1):15-22. PubMed ID: 18039463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocitic leukemia model.
    Trifirò P; Cappa A; Brambillasca S; Botrugno OA; Cera MR; Zuffo RD; Dessanti P; Meroni G; Thaler F; Villa M; Minucci S; Mercurio C; Varasi M; Vianello P
    Future Med Chem; 2017 Jul; 9(11):1161-1174. PubMed ID: 28722470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B.
    Gooden DM; Schmidt DM; Pollock JA; Kabadi AM; McCafferty DG
    Bioorg Med Chem Lett; 2008 May; 18(10):3047-51. PubMed ID: 18242989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
    Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
    Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine.
    Yang M; Culhane JC; Szewczuk LM; Jalili P; Ball HL; Machius M; Cole PA; Yu H
    Biochemistry; 2007 Jul; 46(27):8058-65. PubMed ID: 17569509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
    Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ
    Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1.
    Mould DP; Alli C; Bremberg U; Cartic S; Jordan AM; Geitmann M; Maiques-Diaz A; McGonagle AE; Somervaille TCP; Spencer GJ; Turlais F; Ogilvie D
    J Med Chem; 2017 Oct; 60(19):7984-7999. PubMed ID: 28892629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents.
    Ma LY; Zheng YC; Wang SQ; Wang B; Wang ZR; Pang LP; Zhang M; Wang JW; Ding L; Li J; Wang C; Hu B; Liu Y; Zhang XD; Wang JJ; Wang ZJ; Zhao W; Liu HM
    J Med Chem; 2015 Feb; 58(4):1705-16. PubMed ID: 25610955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Cancer with PCPA-Drug Conjugates: LSD1 Inhibition-Triggered Release of 4-Hydroxytamoxifen.
    Ota Y; Itoh Y; Kaise A; Ohta K; Endo Y; Masuda M; Sowa Y; Sakai T; Suzuki T
    Angew Chem Int Ed Engl; 2016 Dec; 55(52):16115-16118. PubMed ID: 27882656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological evaluation of 5-aminotetrahydroquinoline-based LSD1 inhibitors acting on Asp375.
    Yan J; Gu Y; Sun Y; Zhang Z; Zhang X; Wang X; Wu T; Zhao D; Cheng M
    Arch Pharm (Weinheim); 2021 Aug; 354(8):e2100102. PubMed ID: 33987875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment.
    Ma QS; Zhang YF; Li CY; Zhang WX; Yuan L; Niu JB; Song J; Zhang SY; Liu HM
    Eur J Med Chem; 2023 May; 251():115228. PubMed ID: 36881982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.